Abstract | BACKGROUND/AIMS: METHODS: 5/6-nephrectomized uremic rats were divided into control uremic rats (CRF group), benazepril-treated uremic rats (CRF+B group) and uremic rats receiving benazepril and AST-120 (CRF+BK group). After 14 weeks of treatment renal function and pathological changes were investigated. RESULTS: The progression of renal dysfunction was delayed in both the CRF+B and CRF+BK groups as compared with the CRF group. In the CRF+BK group, the level of serum and urinary indoxyl sulfate and the tubular accumulation of indoxyl sulfate decreased. Both the CRF+B and CRF+BK groups showed lower glomerular sclerosis indices than the CRF group. In the CRF+BK group, but not the CRF+B group, the interstitial fibrosis area and the expression of transforming growth factor (TGF) beta1 and tissue inhibitor of metalloproteinases (TIMP) 1 were decreased as compared with the CRF group. Furthermore, the CRF+BK group showed a smaller interstitial fibrosis area and a lower renal osteopontin expression than the CRF+B group. CONCLUSION:
|
Authors | Isao Aoyama, Kaoru Shimokata, Toshimitsu Niwa |
Journal | Nephron
(Nephron)
Vol. 90
Issue 3
Pg. 297-312
(Mar 2002)
ISSN: 1660-8151 [Print] Switzerland |
PMID | 11867951
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2002 S. Karger AG, Basel |
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Benzazepines
- Oxides
- SPP1 protein, human
- Sialoglycoproteins
- Spp1 protein, rat
- TGFB1 protein, human
- Tgfb1 protein, rat
- Tissue Inhibitor of Metalloproteinase-1
- Transforming Growth Factor beta
- Transforming Growth Factor beta1
- Osteopontin
- Carbon
- AST 120
- Indican
- benazepril
|
Topics |
- Adsorption
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Animals
- Benzazepines
(therapeutic use)
- Blood Pressure
(physiology)
- Carbon
(therapeutic use)
- Cells, Cultured
- Disease Progression
- Drug Therapy, Combination
- Fibroblasts
(metabolism)
- Fibrosis
- Humans
- In Situ Hybridization
- Indican
(blood, urine)
- Kidney
(drug effects, pathology, physiopathology)
- Kidney Diseases
(drug therapy, pathology, physiopathology)
- Male
- Nephrectomy
- Nephrosclerosis
(drug therapy, pathology, physiopathology)
- Osteopontin
- Oxides
(therapeutic use)
- Rats
- Rats, Sprague-Dawley
- Sialoglycoproteins
(genetics, metabolism)
- Tissue Inhibitor of Metalloproteinase-1
(metabolism)
- Transforming Growth Factor beta
(genetics, metabolism)
- Transforming Growth Factor beta1
- Uremia
(drug therapy)
|